This is new to me, where did you read this? can you quote

New Post Public Reply Private Reply Replies (1) Message Board
All Aboard jamiejaytrader #24995
401
Quote:
This is new to me, where did you read this? can you quote that part? perhaps i overlooked something, thanks.


"Following SeD Biomedical's preliminary due diligence, SeD Biomedical has informed Amarantus' management of strategic measures that must be met by creditors and certain other parties as a condition for any investment, loan or asset injection by SeD Biomedical.

Neither SeD Biomedical, Amarantus, nor any individuals or entities affiliated with SeD Biomedical and Amarantus (including the management, directors and shareholders of SeD Biomedical and Amarantus) is able to guarantee Amarantus' management's ability to successfully negotiate with creditors or other parties, raise funds or successfully implement a new strategic direction for Amarantus. In the event that creditors and certain other parties decline to participate in the planned restructuring of liabilities to be developed by Amarantus' management under the supervision of the Board, and to execute such releases as may be required in connection with such restructuring, SeD Biomedical reserves the right to terminate the LOI."

They said if the creditors won't participate in their new plan (not the plan in the binding LOIs with the preferreds), they would terminate the SeD LOI.

Quote:
I recall they did do a valutation on one asset which is worth a minimum of $12.5 million. I'm not sure where i read it but i know this for certain


You don't know this for certain. The preferreds made the release of their liens contingent on a number of things. One was that SeD inject an asset into AMBS. They also required that AMBS hire (and pay for) a valuation firm to value the asset or assets that SeD puts in. The minimum acceptable value was $12.5M. But we have seen no evidence that they have hired a valuation firm or have any money to pay them.

Also, any investment into AMBS or AVDX must be accompanied by a fairness opinion. These things cost a lot of money. Without the bridge, how does AMBS do all of this?

When is the last time the lawyers got paid too?

The lack of the bridge is killing us in my opinion.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

AIP Realty Trust Announces Successful Non-Brokered Offering

Updated Category News Views 177

AIP Realty Trust's Financial Milestone Achieved AIP Realty Trust has made waves in the investment community by successfully finalizing the initial tranche of a significant non-brokered private placement. These efforts have brought in an impressive total of 7,260,000 Preferred Units—Series B Convertible, valued at US$0.50 each, resulting in gross proceeds of...

Continue Reading
Medtronic's BrainSense™ Receives CE Marking for Parkinson's Care

Updated Category News Views 499

Medtronic’s Innovative Approval for Parkinson's Treatment Medtronic plc (NYSE: MDT), a global leader in healthcare technologies, has achieved a significant milestone by receiving CE Mark approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) system and the BrainSense™ Electrode Identifier (EI). This remarkable advancement introduces the world's first...

Continue Reading
Understanding the New Rating for abrdn Asia-Pacific Income Fund

Updated Category News Views 84

KBRA's Rating Insights on abrdn Asia-Pacific Income Fund Recently, KBRA has taken significant steps by assigning a new rating to the Series B Mandatory Redeemable Preferred Shares (MRPS) of abrdn Asia-Pacific Income Fund, Inc. (NYSE: FAX). This rating stands at 'AA-', illustrating the organization's confidence in the stability and security of these investment instruments....

Continue Reading
Protect Your Investment: Join the Applied Therapeutics Class Action

Updated Category News Views 156

Understanding the Class Action for Applied Therapeutics Investors As an investor in Applied Therapeutics, Inc. (APLT), you may have felt the financial impact of recent challenges the company has encountered. The firm is currently facing a class action lawsuit aimed at addressing securities fraud that adversely affected investors between specific dates. This situation is...

Continue Reading
Heritage Capital Group Facilitates Mittauer's Strategic Sale

Updated Category News Views 205

Heritage Capital Group Facilitates Mittauer's Strategic Sale Heritage Capital Group, Inc. ("Heritage"), a respected investment banking and financial advisory firm known for serving middle-market and emerging growth companies, has successfully guided its client, Mittauer & Associates, Inc. ("Mittauer"), through a significant transition in its business landscape. This...

Continue Reading